• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国南方和北方医院和医疗保健保险系统基于记录的重症肌无力流行病学研究。

Hospital and healthcare insurance system record-based epidemiological study of myasthenia gravis in southern and northern China.

机构信息

School of Earth and Environmental Sciences, Queens College, City University of New York, Queens, NY, USA.

Department of Neurology, The First Affiliated Hospital of Sun Yat-sen University, #58 Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, People's Republic of China.

出版信息

Neurol Sci. 2020 May;41(5):1211-1223. doi: 10.1007/s10072-019-04146-1. Epub 2020 Jan 3.

DOI:10.1007/s10072-019-04146-1
PMID:31897952
Abstract

OBJECTIVE

This is the first cross-region epidemiological study of myasthenia gravis (MG) in China. We estimated the incidence, prevalence, and medical costs of MG in southern China and explored the differences between the southern and northern Chinese populations.

METHODS

We collected and analyzed records from 20 hospitals in the southern city, Guangzhou, 13 hospitals in the northern city, Harbin, and two healthcare insurance systems: job based and residence based in Guangzhou during 2000-2017.

RESULTS

(1) The estimated annual incidence of MG was 1.55-3.66 per 100,000, and the estimated prevalence of MG was 2.19-11.07 per 100,000 in southern China based on insurance records. (2) The proportion of hospitalized MG patients in the south-based hospital records was three times as high as that in the north-based hospital records. (3) Female MG prevalence was significantly higher than male MG prevalence in Guangzhou, while the similar gender difference in Harbin was not statistically significant due to higher variation in earlier years. (4) The average expense was $35-42 for each outpatient service and $2526-2673 for each hospitalization expense in the south. (5) Contrary to the increase of insurance-based estimate of MG prevalence, the proportion of hospitalized MG patients did not increase over the years, suggesting rising awareness and utilization of health insurance.

CONCLUSIONS

The southern MG population had a significantly higher prevalence and a lower response threshold to medication than the northern MG population. These results are calling for further investigations on the genetic, cultural, and environmental variations of the Chinese MG populations between north and south.

摘要

目的

这是中国首次进行的重症肌无力(MG)跨区域流行病学研究。我们评估了中国南方MG 的发病率、患病率和医疗费用,并探讨了中国南北方人群之间的差异。

方法

我们收集并分析了 2000-2017 年期间位于南方城市广州的 20 家医院、位于北方城市哈尔滨的 13 家医院以及广州的两种医疗保险系统(基于工作和基于居住地)的记录。

结果

(1)根据保险记录,南方中国 MG 的估计年发病率为 1.55-3.66/10 万,MG 的估计患病率为 2.19-11.07/10 万。(2)南方基于医院记录的住院 MG 患者比例是北方基于医院记录的三倍。(3)在广州,女性 MG 的患病率明显高于男性,而在哈尔滨,由于早年的变异性较大,这种相似的性别差异在统计学上并不显著。(4)南方每次门诊服务的平均费用为 35-42 美元,每次住院费用为 2526-2673 美元。(5)与基于保险的 MG 患病率估计值的增加相反,住院 MG 患者的比例多年来并未增加,这表明人们对健康保险的认识和利用有所提高。

结论

南方 MG 人群的患病率明显较高,对药物的反应阈值也较低。这些结果表明,有必要进一步研究中国南北方 MG 人群的遗传、文化和环境差异。

相似文献

1
Hospital and healthcare insurance system record-based epidemiological study of myasthenia gravis in southern and northern China.中国南方和北方医院和医疗保健保险系统基于记录的重症肌无力流行病学研究。
Neurol Sci. 2020 May;41(5):1211-1223. doi: 10.1007/s10072-019-04146-1. Epub 2020 Jan 3.
2
Out-of-pocket expenses for myasthenia gravis patients in China: a study on patients insured by basic medical insurance in China, 2013-2015.中国重症肌无力患者自付费用研究:2013-2015 年中国基本医疗保险参保患者研究。
Orphanet J Rare Dis. 2020 Jan 14;15(1):13. doi: 10.1186/s13023-019-1289-9.
3
Costs of hospitalization for stroke from two urban health insurance claims data in Guangzhou City, southern China.中国南方广州市两份城市医保理赔数据中脑卒中住院费用。
BMC Health Serv Res. 2019 Sep 18;19(1):671. doi: 10.1186/s12913-019-4530-2.
4
Nationwide population-based epidemiological study of myasthenia gravis in taiwan.台湾重症肌无力的全国基于人群的流行病学研究。
Neuroepidemiology. 2010;35(1):66-71. doi: 10.1159/000311012. Epub 2010 Jun 3.
5
Direct medical costs of end-stage kidney disease and renal replacement therapy: a cohort study in Guangzhou City, southern China.终末期肾病和肾脏替代治疗的直接医疗费用:中国南方广州市的一项队列研究。
BMC Health Serv Res. 2020 Feb 14;20(1):122. doi: 10.1186/s12913-020-4960-x.
6
Epidemiology of myasthenia gravis in France: Incidence, prevalence, and comorbidities based on national healthcare insurance claims data.法国重症肌无力的流行病学:基于国家医保报销数据的发病率、患病率和共病情况。
Rev Neurol (Paris). 2024 May;180(5):451-458. doi: 10.1016/j.neurol.2024.02.392. Epub 2024 Apr 5.
7
Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases.葡萄牙北部重症肌无力的流行病学:病例的频率估计及临床流行病学分布
Muscle Nerve. 2016 Sep;54(3):413-21. doi: 10.1002/mus.25068. Epub 2016 Jul 4.
8
The Epidemiology of Myasthenia Gravis in Korea.韩国重症肌无力的流行病学
Yonsei Med J. 2016 Mar;57(2):419-25. doi: 10.3349/ymj.2016.57.2.419.
9
Incidence of acetylcholine receptor-antibody-positive myasthenia gravis in South Africa.南非乙酰胆碱受体抗体阳性重症肌无力的发病率。
Muscle Nerve. 2015 Apr;51(4):533-7. doi: 10.1002/mus.24348. Epub 2015 Feb 11.
10
Cost analysis of myasthenia gravis from a large U.S. insurance database.从美国大型保险数据库分析重症肌无力的成本。
Muscle Nerve. 2011 Dec;44(6):907-11. doi: 10.1002/mus.22212.

引用本文的文献

1
Epidemiology, Patient Characteristics, and Treatment Patterns of Myasthenia Gravis in Taiwan: A Population-Based Study.台湾重症肌无力的流行病学、患者特征及治疗模式:一项基于人群的研究
Neurol Ther. 2024 Jun;13(3):809-824. doi: 10.1007/s40120-024-00619-4. Epub 2024 Apr 27.
2
Diagnosis and therapy of myasthenia gravis-the patients' perspective: a cross-sectional study.重症肌无力的诊断与治疗——患者视角:一项横断面研究
Front Neurol. 2023 Aug 4;14:1214041. doi: 10.3389/fneur.2023.1214041. eCollection 2023.
3
Epigenome-wide DNA methylation analysis of myasthenia gravis.
重症肌无力的全基因组 DNA 甲基化分析。
FEBS Open Bio. 2023 Jul;13(7):1375-1389. doi: 10.1002/2211-5463.13656. Epub 2023 Jun 10.
4
Mortality of myasthenia gravis: a national population-based study in China.中国基于全国人口的重症肌无力死亡率研究。
Ann Clin Transl Neurol. 2023 Jul;10(7):1095-1105. doi: 10.1002/acn3.51792. Epub 2023 May 22.
5
Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis.吗替麦考酚酯与吗替麦考酚酯联合糖皮质激素治疗重症肌无力的对比研究。
Ann Clin Transl Neurol. 2023 Apr;10(4):589-598. doi: 10.1002/acn3.51746. Epub 2023 Feb 20.
6
The relationship between anthropometric indicators and health-related quality of life in a community-based adult population: A cross-sectional study in Southern China.基于社区的成年人群中人体测量学指标与健康相关生活质量的关系:中国南方的一项横断面研究。
Front Public Health. 2022 Sep 28;10:955615. doi: 10.3389/fpubh.2022.955615. eCollection 2022.
7
Exploring the Potential Mechanism of Qi-Shen-Di-Huang Drug Formulary for Myasthenia Gravis (MG) based on UHPLC-QE-MS Network Pharmacology and Molecular Docking Techniques.基于超高效液相色谱-四极杆飞行时间质谱联用网络药理学和分子对接技术探索杞参地黄方治疗重症肌无力的潜在机制
Evid Based Complement Alternat Med. 2022 Oct 3;2022:7416448. doi: 10.1155/2022/7416448. eCollection 2022.
8
Clinical characteristics and prognosis of amyotrophic lateral sclerosis with autoimmune diseases.伴有自身免疫性疾病的肌萎缩侧索硬化症的临床特征和预后。
PLoS One. 2022 Apr 7;17(4):e0266529. doi: 10.1371/journal.pone.0266529. eCollection 2022.
9
Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations.重症肌无力:流行病学、病理生理学及临床表现
J Clin Med. 2021 May 21;10(11):2235. doi: 10.3390/jcm10112235.
10
The epidemiology of myasthenia gravis.重症肌无力的流行病学。
J Med Life. 2021 Jan-Mar;14(1):7-16. doi: 10.25122/jml-2020-0145.